ACE-031 represents a fundamentally different approach to myostatin inhibition — rather than blocking the ligand directly, it acts as a circulating trap that captures myostatin and related growth-limiting molecules before they can reach muscle tissue receptors.
Research Applications
Myostatin trap research, muscle wasting conditions, Duchenne muscular dystrophy, and lean mass augmentation studies.
Dosage Information (Research Use)
Clinical trial doses: 0.5-3 mg/kg subcutaneously every 2 weeks. Research use only.
Reconstitution & Handling
Reconstitute carefully with sterile water. Protein is sensitive to shaking.
Half-Life & Pharmacokinetics
Approximately 10-15 days due to Fc fusion technology.
Reported Observations in Literature
Clinical trials reported minor epistaxis (nosebleeds) and gingival bleeding, leading to study pause. Muscle efficacy was confirmed.
Key Research References
- Attie KM, et al. “A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.” Muscle Nerve. 2013